Lilly inks second deal with Asian partner this week
This article was originally published in Scrip
The Indianapolis pharma signed a second deal with an Asian company in as many days. Eli Lilly & Co announced on 20 March that it will pay $56m up front to Chinese biotech Innovent Biologics to collaborate on several oncology compounds.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.